Clinical Overview
The introduction of non-VKA oral anticoagulants (NOACs) into clinical practice has produced a wealth of data, changed guideline recommendations, and continues to push into new areas where an anticoagulation strategy may supplement or replace current thrombocardiology strategies for polyvascular protection from clot formation and embolization. There is a need to evaluate the data, clinical implications, and recommendations in secondary prevention of coronary artery disease (CAD) and other polyvascular diseases where an antiplatelet + anticoagulation management strategy has increasingly benefited patients by protecting against clot formation and embolization with NOACs, while keeping bleeding risks acceptable.

Target Audience
Cardiologists, interventional cardiologists, internists, fellows, medical students, pharmacy professionals, and allied health professionals involved in the care of patients with polyvascular disease.

Learning Objectives
1. Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
2. Relate the clinical implications of anticoagulation in patients with coronary artery disease, peripheral artery disease, and other vascular diseases
3. Utilize NOACs at the proper dose for patients with moderate or high risk of major polyvascular events, advising patients of the risks and benefits, and performing proper follow-up
4. Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended

Follow this link for more information and instructions on requesting a Grand Rounds Lecture Program